NovaBridge Biosciences' stock price target has been adjusted from $7.75 to $7.00, indicating a shift in analyst sentiment.The company's strategic partnerships and ongoing clinical trials are crucial factors for investors to watch.Comparatively, IMab (IMAB) receives a positive outlook from analysts, underscoring the impact of analyst ratings on biotech stocks.NovaBridge Biosciences (NASDAQ:NBP) is a biotech company dedicated to developing immuno-oncology agents for cancer treatment. The company is advancing ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether uniQure and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining th ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. Also from this source On this news, Regencell's stock price fell $3.09 per share, or 18.56%, to close at $13.56 per share on November 3, 2025. Pomerantz LLP, with offices in New ...

Question-and-Answer SessionMaybe kick off with a little just a quick look back on the fiscal first quarter, some gives and takes, but you did talk about kind of core growth up 1%, maybe setting aside the cell therapy kind of noise here. We'll unpack that in a minute, but just talk a little bit about what you saw in the quarter.James HippelExecutive VP of Finance & CFO Tycho, thanks for having us. Yes, the overall growth for the quarter was negative 1%, a little bit -- a result that doesn't really reflect ou ...

MediWound (NasdaqGM:MDWD) Q3 2025 Earnings Call November 20, 2025 08:30 AM ET Company ParticipantsBarry Wolfenson - EVP of Strategy and Corporate DevelopmentOfer Gonen - CEODan Ferry - Head of Investor RelationsHani Luxenburg - CFOConference Call ParticipantsMichael Okunewitch - AnalystJosh Jennings - AnalystNone - AnalystJeff Jones - AnalystOperatorGood morning, everyone, and welcome to the MediWound's third quarter 2025 earnings call. All participants will be in a listen-only mode. Should you need assista ...

MediWound (NasdaqGM:MDWD) Q3 2025 Earnings Call November 20, 2025 08:30 AM ET Speaker5Good morning, everyone, and welcome to the MediWound's third quarter 2025 earnings call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then one using a touch-tone telephone. To withdraw your questio ...

Valneva Reports First Nine Months 2025 Financial Results and Provides Corporate Updates November 20, 2025 Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Valneva is a European company. Information distributed is subject to European disclosure requirements that are different from those of the United Stat ...

Analyst Day 2025 November 20, 2025 © 2025 Moderna, Inc. All rights reserved. Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's anticipated commercial growth drivers, including geographic expansion and new product launches; Moderna's ability to achieve up to 10% revenue growth in 2026; Moderna's ability to expand its seasonal vaccine f ...

Conformity with stringent new EU regulations for medical devices confirmed Allows for commercialization of Bentrio in EU member states; facilitates regulatory approval in various other countries Major milestone in international growth strategy HAMILTON, BERMUDA / ACCESS Newswire / November 20, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and supplying nucleic acid delivery technology for partners in biotech and pharma, today announced that ...

SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced successful submission and acceptance of the end-of-phase 1 meeting package to FDA and that the company is on track to hold the meeting later this year. The primary purpose of this meeting is to establish agency feedback and input into the clinical development and regulatory approva ...